Quinagolide

Summary

Quinagolide (CHEMBL2218861) is an approved small molecule (ATC G02CB04); indicated across 1 condition including ovarian hyperstimulation syndrome.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: G02CB04
• Indications: 1 condition
• Clinical trials: 3
• Chemistry: 395.6 Da · C20H33N3O3S

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2218861
Name	Quinagolide
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	55645
ATC	G02CB04
Molecular formula	C20H33N3O3S
Molecular weight	395.6
InChIKey	GDFGTRDCCWFXTG-UHFFFAOYSA-N

SMILES: CCCN1CC(CC2C1CC3=C(C2)C(=CC=C3)O)NS(=O)(=O)N(CC)CC

IUPAC name: 3-(diethylsulfamoylamino)-6-hydroxy-1-propyl-3,4,4a,5,10,10a-hexahydro-2H-benzo[g]quinoline

Also known as: Quinagolida, Quinagolide, QUINAGOLIDE, quinagolide

Parent form; salt/anhydrous children: CHEMBL5316219

Patent coverage: 41 distinct patent families (86 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 73 (85%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 18 (assay-derived). Sample: 5-hydroxytryptamine receptor 2B, Adrenergic receptor alpha-1, Alpha-2C adrenergic receptor, Alpha-2B adrenergic receptor, D(1A) dopamine receptor, Adrenergic receptor alpha-2, Serotonin (5-HT) receptor, Dopamine receptor, 5-hydroxytryptamine receptor 1A, D(2) dopamine receptor, Sodium-dependent noradrenaline transporter, 5-hydroxytryptamine receptor 2A, Alpha-1A adrenergic receptor, Histamine H1 receptor, D(3) dopamine receptor, Kappa-type opioid receptor, Voltage-gated inwardly rectifying potassium channel KCNH2, Nuclear receptor subfamily 1 group I member 2.

Bioactivity

ChEMBL activities: 32 potent at pChembl ≥ 5 of 37 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
DRD3	8.55	AC50	2.8	nM	CHEMBL_ACT_25193307
DRD2	7.82	AC50	15.2	nM	CHEMBL_ACT_25140108
P20288	7.72	IC50	19	nM	CHEMBL_ACT_483401
P20288	7.32	IC50	48	nM	CHEMBL_ACT_431525
P20288	7.32	IC50	48	nM	CHEMBL_ACT_499772
P20288	7.12	IC50	75	nM	CHEMBL_ACT_483402
DRD1	6.82	AC50	150	nM	CHEMBL_ACT_25180304
P20288	6.72	IC50	190	nM	CHEMBL_ACT_431526
P20288	6.72	IC50	190	nM	CHEMBL_ACT_499773
HTR2B	6.49	AC50	324.1	nM	CHEMBL_ACT_25164046
ADRA1A	6.35	AC50	450	nM	CHEMBL_ACT_25229635
HTR1A	5.96	AC50	1100	nM	CHEMBL_ACT_25216807
OPRK1	5.77	AC50	1700	nM	CHEMBL_ACT_25129226
P08909	5.64	IC50	2300	nM	CHEMBL_ACT_483403
NR1I2	5.57	AC50	2700	nM	CHEMBL_ACT_25188028
HRH1	5.55	AC50	2800	nM	CHEMBL_ACT_25212285
P08909	5.5	IC50	3200	nM	CHEMBL_ACT_483404
HTR2B	5.44	AC50	3666	nM	CHEMBL_ACT_25228500
P08909	5.34	IC50	4600	nM	CHEMBL_ACT_431528
P08909	5.34	IC50	4600	nM	CHEMBL_ACT_499775
P08909	5.29	IC50	5100	nM	CHEMBL_ACT_431527
P08909	5.29	IC50	5100	nM	CHEMBL_ACT_499774
HTR2A	5.25	AC50	5600	nM	CHEMBL_ACT_25224975
P19328	5.25	IC50	5600	nM	CHEMBL_ACT_431529
P19328	5.25	IC50	5600	nM	CHEMBL_ACT_499776
P15823	5.22	IC50	6000	nM	CHEMBL_ACT_483406
KCNH2	5.19	AC50	6500	nM	CHEMBL_ACT_25117543
HTR2A	5.19	AC50	6400	nM	CHEMBL_ACT_25226128
NR1I2	5.14	AC50	7200	nM	CHEMBL_ACT_25224230
P19328	5.13	IC50	7400	nM	CHEMBL_ACT_483405
P15823	5.11	IC50	7800	nM	CHEMBL_ACT_431530
P15823	5.11	IC50	7800	nM	CHEMBL_ACT_499777

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 disease in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
ovarian hyperstimulation syndrome	2	MONDO:0011972	MONDO:0011972

Clinical trials

Total trials: 3.

Phase distribution

Phase	Trials
PHASE2	3

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00665041	PHASE2	COMPLETED	Tolerability of Quinagolide in a Dose-titration Regimen in Oocyte Donors at Risk of Developing Ovarian Hyperstimulation Syndrome
NCT03692403	PHASE2	COMPLETED	Randomized Trial Assessing Quinagolide Vaginal Ring for Endometriosis-related Pain
NCT03749109	PHASE2	COMPLETED	Quinagolide Vaginal Ring on Lesion Reduction Assessed by MRI in Women With Endometriosis/Adenomyosis

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).